Gastrointestinal Pharmacology

Correct Answer

C — Serotonin 5-HT3 receptor antagonist used for acute chemotherapy-induced and postoperative nausea and vomiting

Rationale

Ondansetron is the prototype serotonin 5-HT3 receptor antagonist. It blocks serotonin receptors on vagal afferent terminals in the gut wall and on neurons in the nucleus tractus solitarius, interrupting the peripheral serotonin-mediated signal that drives acute chemotherapy-induced nausea and vomiting within the first 24 hours. It is also highly effective for postoperative nausea and vomiting. Metoclopramide is the dopamine D2 antagonist prokinetic (option A); aprepitant is the neurokinin 1 receptor antagonist for delayed emesis (option B); erythromycin at subantimicrobial doses is the motilin receptor agonist (option D).

Correct Answer

A — Metoclopramide

Rationale

Metoclopramide is classified as a dopamine D2 receptor antagonist that produces both prokinetic and antiemetic effects. Ondansetron is a serotonin 5-HT3 receptor antagonist. Aprepitant is a neurokinin 1 receptor antagonist. Dronabinol is a synthetic cannabinoid CB1 receptor partial agonist.

Correct Answer

D — Neurokinin 1 receptor antagonist that blocks substance P-mediated delayed chemotherapy-induced emesis

Rationale

Aprepitant is a neurokinin 1 receptor antagonist. Substance P acting on neurokinin 1 receptors in the central nervous system mediates the delayed phase of chemotherapy-induced nausea and vomiting — the nausea that peaks at 48 to 72 hours after chemotherapy and persists through day 5. Aprepitant blocks this pathway, providing coverage for delayed emesis that serotonin 5-HT3 receptor antagonists alone do not adequately control. It is given orally for 3 days starting on the day of chemotherapy; fosaprepitant is the intravenous prodrug. Dronabinol is the cannabinoid CB1 receptor partial agonist (option C).

Correct Answer

B — Scopolamine

Rationale

Scopolamine is classified as a muscarinic receptor antagonist and is the primary pharmacological agent for motion sickness prevention. Ondansetron is a serotonin 5-HT3 receptor antagonist. Metoclopramide is a dopamine D2 receptor antagonist. Aprepitant is a neurokinin 1 receptor antagonist.

Correct Answer

B — Erythromycin

Rationale

Erythromycin is classified as a motilin receptor agonist, a property that accounts for its prokinetic activity at subantimicrobial doses. Metoclopramide and domperidone are dopamine D2 receptor antagonists. Scopolamine is a muscarinic receptor antagonist.

Correct Answer

D — Synthetic delta-9-tetrahydrocannabinol acting as a partial agonist at cannabinoid CB1 receptors

Rationale

Dronabinol is synthetic delta-9-tetrahydrocannabinol, a partial agonist at cannabinoid CB1 receptors in the central nervous system. It is FDA-approved for chemotherapy-induced nausea and vomiting refractory to conventional antiemetics and for anorexia in AIDS patients. Its Schedule III controlled substance status and adverse effect profile — euphoria or dysphoria, sedation, tachycardia, and impaired psychomotor function — make it poorly tolerated in older adults and limit its role to rescue rather than first-line antiemetic therapy. Palonosetron is the 5-HT3 antagonist with the favorable QTc profile (option C).

Correct Answer

C — It lies outside the blood-brain barrier in the area postrema, allowing circulating emetogenic substances to activate it directly

Rationale

The chemoreceptor trigger zone is located in the area postrema on the floor of the fourth ventricle. Its defining pharmacological feature is that it lies outside the blood-brain barrier, meaning circulating emetogenic substances — chemotherapy drugs, opioids, uremic toxins, digoxin — can reach and activate its dopamine D2, serotonin 5-HT3, and neurokinin 1 receptors without penetrating the brain proper. This makes it the primary target for antiemetics acting on chemotherapy-induced and opioid-induced nausea. Option D is incorrect: the vomiting center in the nucleus tractus solitarius receives four distinct afferent inputs, of which the chemoreceptor trigger zone is only one.

Correct Answer

A — D2 receptor blockade in the gut wall disinhibits acetylcholine release from the myenteric plexus, increasing antral contractility

Rationale

Dopamine normally acts on D2 receptors in the myenteric plexus to inhibit acetylcholine release, reducing antral contractility. Metoclopramide blocks these D2 receptors, relieving this inhibitory dopaminergic tone and allowing cholinergic neurons to release acetylcholine more freely. The resulting increase in acetylcholine-driven antral smooth muscle contraction accelerates gastric emptying. This is a disinhibition mechanism — metoclopramide does not directly stimulate muscle contraction; it removes a brake on the existing cholinergic drive. This same D2 receptor blockade, when it occurs in the central nervous system nigrostriatal pathway rather than the gut, produces the drug's extrapyramidal adverse effects.

Correct Answer

B — Prolonged D2 receptor blockade causes receptor upregulation; the upregulated receptors are supersensitive to endogenous dopamine, producing involuntary movements that persist even without the drug

Rationale

Tardive dyskinesia results from adaptive changes induced by sustained D2 receptor blockade in the nigrostriatal pathway. Chronic blockade causes compensatory upregulation of D2 receptors and postsynaptic dopamine supersensitivity. When the drug is stopped, normal endogenous dopamine release now acts on an expanded, supersensitive receptor population, generating hyperkinetic activity expressed as involuntary orofacial and limb movements. Because the receptor changes are structural and may be permanent, tardive dyskinesia often persists or worsens after drug discontinuation. This is why the FDA requires the metoclopramide black box warning limiting use to 12 weeks maximum for any indication.

Correct Answer

D — Domperidone is a P-glycoprotein substrate at the blood-brain barrier; efflux transport limits its central nervous system penetration while the area postrema remains accessible because it lies outside the barrier

Rationale

Domperidone's peripheral selectivity arises from P-glycoprotein-mediated efflux at the blood-brain barrier, which actively pumps the drug back out of the central nervous system and maintains very low brain concentrations. This prevents blockade of nigrostriatal and tuberoinfundibular D2 receptors, avoiding the extrapyramidal adverse effects and hyperprolactinemia that metoclopramide causes. Crucially, the area postrema — which contains the chemoreceptor trigger zone — lies outside the blood-brain barrier and remains fully accessible to domperidone, allowing antiemetic activity. Despite its favorable central nervous system profile, domperidone prolongs the QTc interval through cardiac potassium channel blockade and is not FDA-approved in the United States.

Correct Answer

A — Substantially longer half-life and higher 5-HT3 receptor affinity, providing more durable receptor occupancy through the delayed emesis window

Rationale

Palonosetron has a half-life of approximately 40 hours compared to ondansetron's 3 to 4 hours, and binds the 5-HT3 receptor with roughly 30-fold higher affinity. These pharmacokinetic and pharmacodynamic differences translate into more sustained receptor blockade through the 24 to 120-hour delayed emesis window. Palonosetron does not have neurokinin 1 receptor antagonist activity — that mechanism belongs to aprepitant and other NK1 antagonists (option B). Palonosetron also has minimal cardiac potassium channel affinity and does not cause clinically significant QTc prolongation, which is an additional clinical advantage over ondansetron.

Correct Answer

C — Aprepitant is a moderate CYP3A4 inhibitor; reduced dexamethasone metabolism raises its plasma concentrations, so the dose is lowered to maintain the intended exposure

Rationale

Dexamethasone is a CYP3A4 substrate. Aprepitant is a moderate inhibitor of CYP3A4, which substantially reduces dexamethasone clearance and increases its plasma concentrations. If dexamethasone were given at full antiemetic doses alongside aprepitant, the patient would receive a significantly higher effective dexamethasone exposure than intended, increasing the risk of hyperglycemia, insomnia, and mood disturbance. The standard solution is to reduce the dexamethasone dose by approximately 50 percent when co-administered with aprepitant. Aprepitant also induces CYP2C9 — not CYP3A4 — which reduces warfarin concentrations and requires INR monitoring in anticoagulated patients (option A describes the wrong enzyme and the wrong direction of the interaction).

Correct Answer

D — Continuous motilin receptor agonism causes receptor downregulation, and tachyphylaxis develops as receptor density falls below the threshold needed for effective antral contraction

Rationale

Erythromycin's prokinetic effect depends on motilin receptor activation. Continuous agonist stimulation of G protein-coupled receptors characteristically leads to receptor downregulation — internalization and degradation of surface receptors — which reduces the cell's responsiveness to continued agonist exposure. For erythromycin, this receptor downregulation produces rapid tachyphylaxis within days to weeks of continuous use. The drug remains available and is not being cleared faster; the target itself has become less responsive. This mechanism fundamentally limits erythromycin to short-term or intermittent use and explains why it is reserved for acute gastroparetic crises rather than chronic management.

Correct Answer

B — Ondansetron blocks 5-HT3 receptors for acute emesis; aprepitant blocks neurokinin 1 receptors for delayed emesis; dexamethasone provides adjunct benefit through incompletely understood mechanisms

Rationale

The three-drug prophylaxis regimen for highly emetogenic chemotherapy targets two distinct phases with complementary mechanisms. The acute phase (first 24 hours) is driven predominantly by enterochromaffin cell serotonin release activating vagal 5-HT3 receptors; ondansetron or palonosetron blocks this pathway. The delayed phase (48 to 120 hours) is mediated by substance P acting on central neurokinin 1 receptors; aprepitant blocks this pathway. Dexamethasone is added as an adjunct that consistently improves complete response rates by 15 to 25 percentage points through mechanisms that are not fully understood but may involve reduced prostaglandin synthesis and reduced serotonin release from enterochromaffin cells. Understanding which phase each drug targets explains why neither ondansetron alone nor aprepitant alone provides complete coverage.

Correct Answer

C — Metoclopramide's central dopamine D2 blockade worsens motor function in a patient whose disease is defined by nigrostriatal dopamine deficiency

Rationale

Parkinson disease results from progressive degeneration of nigrostriatal dopaminergic neurons, producing a state of relative dopamine deficiency in the basal ganglia that underlies the motor features of the disease. Metoclopramide's central D2 receptor blockade in the nigrostriatal pathway superimposes pharmacological dopamine antagonism on this pre-existing deficit, acutely worsening bradykinesia, rigidity, and tremor. This is a specific contraindication explicitly stated for metoclopramide. The preferred prokinetic alternative in Parkinson disease patients is domperidone via expanded access, because its P-glycoprotein-mediated blood-brain barrier exclusion prevents central D2 blockade while preserving peripheral prokinetic and antiemetic activity through the accessible area postrema.

Correct Answer

A — Ondansetron controls acute emesis within the first 24 hours through 5-HT3 blockade, but substance P-mediated neurokinin 1 receptor activation drives delayed emesis from days 2 through 5 that ondansetron does not adequately suppress

Rationale

Chemotherapy-induced nausea and vomiting comprises two mechanistically distinct phases. The acute phase (0 to 24 hours) is dominated by enterochromaffin cell serotonin release that activates vagal 5-HT3 receptors; ondansetron effectively controls this. The delayed phase (24 to 120 hours) is mediated by substance P acting on neurokinin 1 receptors in the central nervous system — a pathway that serotonin 5-HT3 antagonists do not block. Aprepitant, a neurokinin 1 receptor antagonist, specifically addresses the delayed phase and substantially reduces the rate of delayed emesis when added to 5-HT3 antagonist-based regimens. Highly emetogenic chemotherapy agents such as cisplatin reliably trigger both phases, making three-drug prophylaxis the standard of care.

Correct Answer

B — Sustained nigrostriatal D2 receptor blockade leads to receptor upregulation and dopamine supersensitivity; normal dopamine release now drives hyperkinetic movements through the supersensitive receptor population

Rationale

This patient has tardive dyskinesia from metoclopramide use beyond the FDA-mandated 12-week maximum. Sustained dopamine D2 receptor blockade in the nigrostriatal pathway triggers a compensatory adaptive response: upregulation of postsynaptic D2 receptors and increased dopamine receptor sensitivity. Once this supersensitivity is established, normal endogenous dopamine release generates disproportionate receptor activation, producing involuntary hyperkinetic movements — classically repetitive orofacial movements including chewing, lip-smacking, and tongue protrusion. The condition is often irreversible even after the drug is stopped, which is precisely why the FDA black box warning prohibits metoclopramide use for more than 12 weeks for any indication.

Correct Answer

D — Blockade of muscarinic M1 receptors on vestibular nucleus neurons, interrupting the transmission of inner-ear motion signals to the vomiting center

Rationale

Motion sickness is driven by the vestibular afferent pathway — inner-ear motion detection generates signals that travel via the vestibular nuclei to the vomiting center in the nucleus tractus solitarius. This afferent input is mediated through muscarinic M1 receptors on vestibular nucleus neurons. Scopolamine, a muscarinic antagonist, blocks this pathway and is the most effective pharmacotherapy for motion sickness. The transdermal patch provides 72 hours of continuous drug delivery. Dopamine D2 antagonists (option A) target chemoreceptor trigger zone blood-borne stimuli; 5-HT3 antagonists (option B) target the peripheral vagal serotonin pathway relevant to chemotherapy-induced emesis; NK1 antagonists (option C) address the delayed chemotherapy-induced emesis pathway. None of these mechanisms addresses the vestibular input that defines motion sickness.